<?xml version='1.0' encoding='UTF-8'?>
<Organism_Record>
  <Organism_ID>ASD06710000_1</Organism_ID>
  <Organism>Human</Organism>
  <Organism_Latin>Homo sapiens</Organism_Latin>
  <UniProt_ID>P10275</UniProt_ID>
  <Seq_Length>919</Seq_Length>
  <Molecule_Weight>98989</Molecule_Weight>
  <KEGG_ID>hsa:367</KEGG_ID>
  <Orthology_ID>K08557</Orthology_ID>
  <EBI_ID>EBI-608057</EBI_ID>
  <Function_Summary>Steroid hormone receptors are ligand-activated transcription factors that regulate eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Transcription factor activity is modulated by bound coactivator and corepressor proteins. Transcription activation is down-regulated by NR0B2. Activated, but not phosphorylated, by HIPK3 and ZIPK/DAPK3.</Function_Summary>
  <Pfam_ID>PF02166:Androgen_recep@@PF00104:Hormone_recep@@PF00105:zf-C4</Pfam_ID>
  <Allosteric_Activator_Count>0</Allosteric_Activator_Count>
  <Allosteric_Inhibitor_Count>21</Allosteric_Inhibitor_Count>
  <Allosteric_Regulator_Count>44</Allosteric_Regulator_Count>
  <Alias_List>
      <Alias>Dihydrotestosterone receptor</Alias>
      <Alias>Nuclear receptor subfamily 3 group C member 4</Alias>
  </Alias_List>
  <Function_List>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with a steroid, any of a large group of substances that have in common a ring system based on 1,2-cyclopentanoperhydrophenanthrene.</Detail>
      <Keyword>Steroid binding</Keyword>
      <Ontology_ID>GO:0005496</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Combining with an extracellular or intracellular messenger to initiate a change in cell activity.</Detail>
      <Keyword>Receptor activity</Keyword>
      <Ontology_ID>GO:0004872</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with a lipid.</Detail>
      <Keyword>Lipid binding</Keyword>
      <Ontology_ID>GO:0008289</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with the beta subunit of the catenin complex.</Detail>
      <Keyword>Beta-catenin binding</Keyword>
      <Ontology_ID>GO:0008013</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with zinc (Zn) ions.</Detail>
      <Keyword>Zinc ion binding</Keyword>
      <Ontology_ID>GO:0008270</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>The formation of a protein dimer, a macromolecular structure consists of two noncovalently associated identical or nonidentical subunits.</Detail>
      <Keyword>Protein dimerization activity</Keyword>
      <Ontology_ID>GO:0046983</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with any androgen, male sex hormones.</Detail>
      <Keyword>Androgen binding</Keyword>
      <Ontology_ID>GO:0005497</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with a DNA region that regulates the transcription of a region of DNA, which may be a gene, cistron, or operon. Binding may occur as a sequence specific interaction or as an interaction observed only once a factor has been recruited to the DNA by other factors.</Detail>
      <Keyword>Transcription regulatory region DNA binding</Keyword>
      <Ontology_ID>GO:0044212</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Protein that positively regulates either the transcription of one or more genes, or the translation of mRNA.</Detail>
      <Keyword>Activator</Keyword>
      <Ontology_ID>KW-0010</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with a transcription factor, any protein required to initiate or regulate transcription.</Detail>
      <Keyword>Transcription factor binding</Keyword>
      <Ontology_ID>GO:0008134</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with any metal ion.</Detail>
      <Keyword>Metal ion binding</Keyword>
      <Ontology_ID>GO:0046872</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with chromatin, the network of fibers of DNA and protein that make up the chromosomes of the eukaryotic nucleus during interphase.</Detail>
      <Keyword>Chromatin binding</Keyword>
      <Ontology_ID>GO:0003682</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Combining with an androgen to initiate a change in cell activity.</Detail>
      <Keyword>Androgen receptor activity</Keyword>
      <Ontology_ID>GO:0004882</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with any enzyme.</Detail>
      <Keyword>Enzyme binding</Keyword>
      <Ontology_ID>GO:0019899</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Any molecular function by which a gene product interacts selectively with DNA (deoxyribonucleic acid).</Detail>
      <Keyword>DNA binding</Keyword>
      <Ontology_ID>GO:0003677</Ontology_ID>
    </Funtion>
  </Function_List>
  <Mutation_List>
    <Muntion>
      <Position>611</Position>
      <Original>Cys</Original>
      <Variation>Tyr</Variation>
    </Muntion>
    <Muntion>
      <Position>866</Position>
      <Original>Val</Original>
      <Variation>Met</Variation>
    </Muntion>
    <Muntion>
      <Position>607</Position>
      <Original>Arg</Original>
      <Variation>Gln</Variation>
    </Muntion>
    <Muntion>
      <Position>877</Position>
      <Original>Thr</Original>
      <Variation>Ala</Variation>
    </Muntion>
    <Muntion>
      <Position>879</Position>
      <Original>Asp</Original>
      <Variation>Tyr</Variation>
    </Muntion>
    <Muntion>
      <Position>601</Position>
      <Original>Cys</Original>
      <Variation>Phe</Variation>
    </Muntion>
    <Muntion>
      <Position>686</Position>
      <Original>Cys</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>790</Position>
      <Original>Leu</Original>
      <Variation>Phe</Variation>
    </Muntion>
    <Muntion>
      <Position>763</Position>
      <Original>Tyr</Original>
      <Variation>Cys</Variation>
    </Muntion>
    <Muntion>
      <Position>580</Position>
      <Original>Lys</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>751</Position>
      <Original>Trp</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>896</Position>
      <Original>Ala</Original>
      <Variation>Thr</Variation>
    </Muntion>
    <Muntion>
      <Position>766</Position>
      <Original>Pro</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>754</Position>
      <Original>Phe</Original>
      <Variation>Val</Variation>
    </Muntion>
    <Muntion>
      <Position>820</Position>
      <Original>Gly</Original>
      <Variation>Ala</Variation>
    </Muntion>
    <Muntion>
      <Position>812</Position>
      <Original>Leu</Original>
      <Variation>Phe</Variation>
    </Muntion>
    <Muntion>
      <Position>604</Position>
      <Original>Asp</Original>
      <Variation>Tyr</Variation>
    </Muntion>
    <Muntion>
      <Position>749</Position>
      <Original>Met</Original>
      <Variation>Val</Variation>
    </Muntion>
    <Muntion>
      <Position>57</Position>
      <Original>Leu</Original>
      <Variation>Gln</Variation>
    </Muntion>
    <Muntion>
      <Position>756</Position>
      <Original>Asn</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>723</Position>
      <Original>Pro</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>112</Position>
      <Original>Gln</Original>
      <Variation>His</Variation>
    </Muntion>
    <Muntion>
      <Position>581</Position>
      <Original>Val</Original>
      <Variation>Phe</Variation>
    </Muntion>
    <Muntion>
      <Position>863</Position>
      <Original>Leu</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>748</Position>
      <Original>Ala</Original>
      <Variation>Val</Variation>
    </Muntion>
    <Muntion>
      <Position>759</Position>
      <Original>Ser</Original>
      <Variation>Pro</Variation>
    </Muntion>
    <Muntion>
      <Position>608</Position>
      <Original>Arg</Original>
      <Variation>Lys</Variation>
    </Muntion>
    <Muntion>
      <Position>684</Position>
      <Original>Val</Original>
      <Variation>Ile</Variation>
    </Muntion>
    <Muntion>
      <Position>724</Position>
      <Original>Gly</Original>
      <Variation>Asp</Variation>
    </Muntion>
    <Muntion>
      <Position>806</Position>
      <Original>Cys</Original>
      <Variation>Tyr</Variation>
    </Muntion>
    <Muntion>
      <Position>712</Position>
      <Original>Leu</Original>
      <Variation>Phe</Variation>
    </Muntion>
    <Muntion>
      <Position>705</Position>
      <Original>Asn</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>596</Position>
      <Original>Ala</Original>
      <Variation>Thr</Variation>
    </Muntion>
    <Muntion>
      <Position>864</Position>
      <Original>Asp</Original>
      <Variation>Asn</Variation>
    </Muntion>
    <Muntion>
      <Position>54</Position>
      <Original>Leu</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>576</Position>
      <Original>Cys</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>705</Position>
      <Original>Asn</Original>
      <Variation>Tyr</Variation>
    </Muntion>
    <Muntion>
      <Position>742</Position>
      <Original>Met</Original>
      <Variation>Ile</Variation>
    </Muntion>
    <Muntion>
      <Position>180</Position>
      <Original>Lys</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>831</Position>
      <Original>Arg</Original>
      <Variation>Leu</Variation>
    </Muntion>
    <Muntion>
      <Position>491</Position>
      <Original>Gly</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>586</Position>
      <Original>Ala</Original>
      <Variation>Val</Variation>
    </Muntion>
    <Muntion>
      <Position>390</Position>
      <Original>Pro</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>846</Position>
      <Original>Arg</Original>
      <Variation>Gly</Variation>
    </Muntion>
    <Muntion>
      <Position>677</Position>
      <Original>Leu</Original>
      <Variation>Pro</Variation>
    </Muntion>
    <Muntion>
      <Position>722</Position>
      <Original>Leu</Original>
      <Variation>Phe</Variation>
    </Muntion>
    <Muntion>
      <Position>645</Position>
      <Original>Ala</Original>
      <Variation>Asp</Variation>
    </Muntion>
    <Muntion>
      <Position>787</Position>
      <Original>Met</Original>
      <Variation>Val</Variation>
    </Muntion>
    <Muntion>
      <Position>917</Position>
      <Original>His</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>841</Position>
      <Original>Ile</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>827</Position>
      <Original>Phe</Original>
      <Variation>Val</Variation>
    </Muntion>
    <Muntion>
      <Position>587</Position>
      <Original>Ala</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>840</Position>
      <Original>Arg</Original>
      <Variation>Cys</Variation>
    </Muntion>
    <Muntion>
      <Position>340</Position>
      <Original>Pro</Original>
      <Variation>Leu</Variation>
    </Muntion>
    <Muntion>
      <Position>733</Position>
      <Original>Gln</Original>
      <Variation>His</Variation>
    </Muntion>
    <Muntion>
      <Position>717</Position>
      <Original>Lys</Original>
      <Variation>Glu</Variation>
    </Muntion>
    <Muntion>
      <Position>774</Position>
      <Original>Arg</Original>
      <Variation>His</Variation>
    </Muntion>
    <Muntion>
      <Position>548</Position>
      <Original>Pro</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>579</Position>
      <Original>Cys</Original>
      <Variation>Tyr</Variation>
    </Muntion>
    <Muntion>
      <Position>749</Position>
      <Original>Met</Original>
      <Variation>Ile</Variation>
    </Muntion>
    <Muntion>
      <Position>748</Position>
      <Original>Ala</Original>
      <Variation>Asp</Variation>
    </Muntion>
    <Muntion>
      <Position>890</Position>
      <Original>Asp</Original>
      <Variation>Asn</Variation>
    </Muntion>
    <Muntion>
      <Position>732</Position>
      <Original>Asp</Original>
      <Variation>Asn</Variation>
    </Muntion>
    <Muntion>
      <Position>842</Position>
      <Original>Ile</Original>
      <Variation>Thr</Variation>
    </Muntion>
    <Muntion>
      <Position>840</Position>
      <Original>Arg</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>855</Position>
      <Original>Arg</Original>
      <Variation>Cys</Variation>
    </Muntion>
    <Muntion>
      <Position>571</Position>
      <Original>Tyr</Original>
      <Variation>Cys</Variation>
    </Muntion>
    <Muntion>
      <Position>880</Position>
      <Original>Leu</Original>
      <Variation>Gln</Variation>
    </Muntion>
    <Muntion>
      <Position>791</Position>
      <Original>Ser</Original>
      <Variation>Pro</Variation>
    </Muntion>
    <Muntion>
      <Position>630</Position>
      <Original>Lys</Original>
      <Variation>Thr</Variation>
    </Muntion>
    <Muntion>
      <Position>616</Position>
      <Original>Leu</Original>
      <Variation>Pro</Variation>
    </Muntion>
    <Muntion>
      <Position>701</Position>
      <Original>Leu</Original>
      <Variation>His</Variation>
    </Muntion>
    <Muntion>
      <Position>877</Position>
      <Original>Thr</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>767</Position>
      <Original>Asp</Original>
      <Variation>Glu</Variation>
    </Muntion>
    <Muntion>
      <Position>682</Position>
      <Original>Pro</Original>
      <Variation>Thr</Variation>
    </Muntion>
    <Muntion>
      <Position>701</Position>
      <Original>Leu</Original>
      <Variation>Phe</Variation>
    </Muntion>
    <Muntion>
      <Position>715</Position>
      <Original>Val</Original>
      <Variation>Met</Variation>
    </Muntion>
    <Muntion>
      <Position>902</Position>
      <Original>Gln</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>754</Position>
      <Original>Phe</Original>
      <Variation>Leu</Variation>
    </Muntion>
    <Muntion>
      <Position>708</Position>
      <Original>Gly</Original>
      <Variation>Ala</Variation>
    </Muntion>
    <Muntion>
      <Position>807</Position>
      <Original>Met</Original>
      <Variation>Val</Variation>
    </Muntion>
    <Muntion>
      <Position>750</Position>
      <Original>Gly</Original>
      <Variation>Asp</Variation>
    </Muntion>
    <Muntion>
      <Position>728</Position>
      <Original>Leu</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>762</Position>
      <Original>Leu</Original>
      <Variation>Phe</Variation>
    </Muntion>
    <Muntion>
      <Position>390</Position>
      <Original>Pro</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>768</Position>
      <Original>Leu</Original>
      <Variation>Pro</Variation>
    </Muntion>
    <Muntion>
      <Position>909</Position>
      <Original>Gly</Original>
      <Variation>Glu</Variation>
    </Muntion>
    <Muntion>
      <Position>629</Position>
      <Original>Arg</Original>
      <Variation>Gln</Variation>
    </Muntion>
    <Muntion>
      <Position>784</Position>
      <Original>Cys</Original>
      <Variation>Tyr</Variation>
    </Muntion>
    <Muntion>
      <Position>582</Position>
      <Original>Phe</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>910</Position>
      <Original>Lys</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>834</Position>
      <Original>Tyr</Original>
      <Variation>Cys</Variation>
    </Muntion>
    <Muntion>
      <Position>647</Position>
      <Original>Ser</Original>
      <Variation>Asn</Variation>
    </Muntion>
    <Muntion>
      <Position>687</Position>
      <Original>Ala</Original>
      <Variation>Val</Variation>
    </Muntion>
    <Muntion>
      <Position>576</Position>
      <Original>Cys</Original>
      <Variation>Phe</Variation>
    </Muntion>
    <Muntion>
      <Position>870</Position>
      <Original>Ala</Original>
      <Variation>Val</Variation>
    </Muntion>
    <Muntion>
      <Position>266</Position>
      <Original>Met</Original>
      <Variation>Thr</Variation>
    </Muntion>
    <Muntion>
      <Position>874</Position>
      <Original>His</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>615</Position>
      <Original>Arg</Original>
      <Variation>His</Variation>
    </Muntion>
    <Muntion>
      <Position>758</Position>
      <Original>Asn</Original>
      <Variation>Thr</Variation>
    </Muntion>
    <Muntion>
      <Position>840</Position>
      <Original>Arg</Original>
      <Variation>His</Variation>
    </Muntion>
    <Muntion>
      <Position>782</Position>
      <Original>Ser</Original>
      <Variation>Asn</Variation>
    </Muntion>
    <Muntion>
      <Position>886</Position>
      <Original>Met</Original>
      <Variation>Val</Variation>
    </Muntion>
    <Muntion>
      <Position>854</Position>
      <Original>Arg</Original>
      <Variation>Lys</Variation>
    </Muntion>
    <Muntion>
      <Position>547</Position>
      <Original>Leu</Original>
      <Variation>Phe</Variation>
    </Muntion>
    <Muntion>
      <Position>619</Position>
      <Original>Cys</Original>
      <Variation>Tyr</Variation>
    </Muntion>
    <Muntion>
      <Position>891</Position>
      <Original>Phe</Original>
      <Variation>Leu</Variation>
    </Muntion>
    <Muntion>
      <Position>755</Position>
      <Original>Thr</Original>
      <Variation>Ala</Variation>
    </Muntion>
    <Muntion>
      <Position>798</Position>
      <Original>Gln</Original>
      <Variation>Glu</Variation>
    </Muntion>
    <Muntion>
      <Position>703</Position>
      <Original>Ser</Original>
      <Variation>Cys</Variation>
    </Muntion>
    <Muntion>
      <Position>528</Position>
      <Original>Asp</Original>
      <Variation>Gly</Variation>
    </Muntion>
    <Muntion>
      <Position>703</Position>
      <Original>Ser</Original>
      <Variation>Gly</Variation>
    </Muntion>
    <Muntion>
      <Position>870</Position>
      <Original>Ala</Original>
      <Variation>Gly</Variation>
    </Muntion>
    <Muntion>
      <Position>765</Position>
      <Original>Ala</Original>
      <Variation>Val</Variation>
    </Muntion>
    <Muntion>
      <Position>711</Position>
      <Original>Gln</Original>
      <Variation>Glu</Variation>
    </Muntion>
    <Muntion>
      <Position>794</Position>
      <Original>Phe</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>881</Position>
      <Original>Leu</Original>
      <Variation>Val</Variation>
    </Muntion>
    <Muntion>
      <Position>840</Position>
      <Original>Arg</Original>
      <Variation>Gly</Variation>
    </Muntion>
    <Muntion>
      <Position>688</Position>
      <Original>Gly</Original>
      <Variation>Glu</Variation>
    </Muntion>
    <Muntion>
      <Position>757</Position>
      <Original>Val</Original>
      <Variation>Ala</Variation>
    </Muntion>
    <Muntion>
      <Position>874</Position>
      <Original>His</Original>
      <Variation>Tyr</Variation>
    </Muntion>
    <Muntion>
      <Position>764</Position>
      <Original>Phe</Original>
      <Variation>Leu</Variation>
    </Muntion>
    <Muntion>
      <Position>763</Position>
      <Original>Tyr</Original>
      <Variation>His</Variation>
    </Muntion>
    <Muntion>
      <Position>573</Position>
      <Original>Ala</Original>
      <Variation>Asp</Variation>
    </Muntion>
    <Muntion>
      <Position>695</Position>
      <Original>Asp</Original>
      <Variation>Val</Variation>
    </Muntion>
    <Muntion>
      <Position>585</Position>
      <Original>Arg</Original>
      <Variation>Lys</Variation>
    </Muntion>
    <Muntion>
      <Position>671</Position>
      <Original>Pro</Original>
      <Variation>His</Variation>
    </Muntion>
    <Muntion>
      <Position>855</Position>
      <Original>Arg</Original>
      <Variation>His</Variation>
    </Muntion>
    <Muntion>
      <Position>864</Position>
      <Original>Asp</Original>
      <Variation>Gly</Variation>
    </Muntion>
    <Muntion>
      <Position>743</Position>
      <Original>Gly</Original>
      <Variation>Val</Variation>
    </Muntion>
    <Muntion>
      <Position>889</Position>
      <Original>Val</Original>
      <Variation>Met</Variation>
    </Muntion>
    <Muntion>
      <Position>727</Position>
      <Original>Asn</Original>
      <Variation>Lys</Variation>
    </Muntion>
    <Muntion>
      <Position>702</Position>
      <Original>Ser</Original>
      <Variation>Ala</Variation>
    </Muntion>
    <Muntion>
      <Position>866</Position>
      <Original>Val</Original>
      <Variation>Leu</Variation>
    </Muntion>
    <Muntion>
      <Position>909</Position>
      <Original>Gly</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>742</Position>
      <Original>Met</Original>
      <Variation>Val</Variation>
    </Muntion>
    <Muntion>
      <Position>575</Position>
      <Original>Thr</Original>
      <Variation>Ala</Variation>
    </Muntion>
    <Muntion>
      <Position>568</Position>
      <Original>Gly</Original>
      <Variation>Val</Variation>
    </Muntion>
    <Muntion>
      <Position>903</Position>
      <Original>Val</Original>
      <Variation>Met</Variation>
    </Muntion>
    <Muntion>
      <Position>807</Position>
      <Original>Met</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>788</Position>
      <Original>Arg</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>269</Position>
      <Original>Pro</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>856</Position>
      <Original>Phe</Original>
      <Variation>Leu</Variation>
    </Muntion>
    <Muntion>
      <Position>683</Position>
      <Original>Gly</Original>
      <Variation>Ala</Variation>
    </Muntion>
    <Muntion>
      <Position>744</Position>
      <Original>Leu</Original>
      <Variation>Phe</Variation>
    </Muntion>
    <Muntion>
      <Position>759</Position>
      <Original>Ser</Original>
      <Variation>Phe</Variation>
    </Muntion>
    <Muntion>
      <Position>664</Position>
      <Original>Ile</Original>
      <Variation>Asn</Variation>
    </Muntion>
    <Muntion>
      <Position>779</Position>
      <Original>Arg</Original>
      <Variation>Trp</Variation>
    </Muntion>
    <Muntion>
      <Position>750</Position>
      <Original>Gly</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>710</Position>
      <Original>Arg</Original>
      <Variation>Thr</Variation>
    </Muntion>
    <Muntion>
      <Position>721</Position>
      <Original>Ala</Original>
      <Variation>Thr</Variation>
    </Muntion>
    <Muntion>
      <Position>720</Position>
      <Original>Lys</Original>
      <Variation>Glu</Variation>
    </Muntion>
    <Muntion>
      <Position>726</Position>
      <Original>Arg</Original>
      <Variation>Leu</Variation>
    </Muntion>
    <Muntion>
      <Position>616</Position>
      <Original>Leu</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>670</Position>
      <Original>Gln</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>919</Position>
      <Original>Gln</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>708</Position>
      <Original>Gly</Original>
      <Variation>Val</Variation>
    </Muntion>
    <Muntion>
      <Position>831</Position>
      <Original>Arg</Original>
      <Variation>Gln</Variation>
    </Muntion>
    <Muntion>
      <Position>741</Position>
      <Original>Trp</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>774</Position>
      <Original>Arg</Original>
      <Variation>Cys</Variation>
    </Muntion>
    <Muntion>
      <Position>748</Position>
      <Original>Ala</Original>
      <Variation>Thr</Variation>
    </Muntion>
    <Muntion>
      <Position>892</Position>
      <Original>Pro</Original>
      <Variation>Leu</Variation>
    </Muntion>
    <Muntion>
      <Position>574</Position>
      <Original>Leu</Original>
      <Variation>Pro</Variation>
    </Muntion>
    <Muntion>
      <Position>725</Position>
      <Original>Phe</Original>
      <Variation>Leu</Variation>
    </Muntion>
    <Muntion>
      <Position>615</Position>
      <Original>Arg</Original>
      <Variation>Pro</Variation>
    </Muntion>
    <Muntion>
      <Position>772</Position>
      <Original>Glu</Original>
      <Variation>Ala</Variation>
    </Muntion>
    <Muntion>
      <Position>772</Position>
      <Original>Glu</Original>
      <Variation>Gly</Variation>
    </Muntion>
    <Muntion>
      <Position>745</Position>
      <Original>Met</Original>
      <Variation>Thr</Variation>
    </Muntion>
    <Muntion>
      <Position>568</Position>
      <Original>Gly</Original>
      <Variation>Trp</Variation>
    </Muntion>
    <Muntion>
      <Position>672</Position>
      <Original>Ile</Original>
      <Variation>Thr</Variation>
    </Muntion>
    <Muntion>
      <Position>579</Position>
      <Original>Cys</Original>
      <Variation>Phe</Variation>
    </Muntion>
    <Muntion>
      <Position>707</Position>
      <Original>Leu</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>807</Position>
      <Original>Met</Original>
      <Variation>Thr</Variation>
    </Muntion>
    <Muntion>
      <Position>907</Position>
      <Original>Leu</Original>
      <Variation>Phe</Variation>
    </Muntion>
    <Muntion>
      <Position>582</Position>
      <Original>Phe</Original>
      <Variation>Tyr</Variation>
    </Muntion>
    <Muntion>
      <Position>205</Position>
      <Original>Ser</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>911</Position>
      <Original>Val</Original>
      <Variation>Leu</Variation>
    </Muntion>
    <Muntion>
      <Position>700</Position>
      <Original>Leu</Original>
      <Variation>Met</Variation>
    </Muntion>
    <Muntion>
      <Position>64</Position>
      <Original>Gln</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>771</Position>
      <Original>Asn</Original>
      <Variation>His</Variation>
    </Muntion>
    <Muntion>
      <Position>732</Position>
      <Original>Asp</Original>
      <Variation>Tyr</Variation>
    </Muntion>
    <Muntion>
      <Position>895</Position>
      <Original>Met</Original>
      <Variation>Thr</Variation>
    </Muntion>
    <Muntion>
      <Position>737</Position>
      <Original>Ile</Original>
      <Variation>Thr</Variation>
    </Muntion>
    <Muntion>
      <Position>610</Position>
      <Original>Asn</Original>
      <Variation>Thr</Variation>
    </Muntion>
    <Muntion>
      <Position>597</Position>
      <Original>Ser</Original>
      <Variation>Thr</Variation>
    </Muntion>
    <Muntion>
      <Position>255</Position>
      <Original>Leu</Original>
      <Variation>Pro</Variation>
    </Muntion>
    <Muntion>
      <Position>681</Position>
      <Original>Glu</Original>
      <Variation>Lys</Variation>
    </Muntion>
    <Muntion>
      <Position>743</Position>
      <Original>Gly</Original>
      <Variation>Glu</Variation>
    </Muntion>
    <Muntion>
      <Position>443</Position>
      <Original>Gln</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>214</Position>
      <Original>Gly</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>793</Position>
      <Original>Glu</Original>
      <Variation>Asp</Variation>
    </Muntion>
    <Muntion>
      <Position>617</Position>
      <Original>Arg</Original>
      <Variation>Pro</Variation>
    </Muntion>
    <Muntion>
      <Position>830</Position>
      <Original>Leu</Original>
      <Variation>Pro</Variation>
    </Muntion>
    <Muntion>
      <Position>898</Position>
      <Original>Ile</Original>
      <Variation>Thr</Variation>
    </Muntion>
    <Muntion>
      <Position>869</Position>
      <Original>Ile</Original>
      <Variation>Met</Variation>
    </Muntion>
    <Muntion>
      <Position>695</Position>
      <Original>Asp</Original>
      <Variation>His</Variation>
    </Muntion>
    <Muntion>
      <Position>2</Position>
      <Original>Glu</Original>
      <Variation>Lys</Variation>
    </Muntion>
    <Muntion>
      <Position>866</Position>
      <Original>Val</Original>
      <Variation>Glu</Variation>
    </Muntion>
    <Muntion>
      <Position>597</Position>
      <Original>Ser</Original>
      <Variation>Gly</Variation>
    </Muntion>
    <Muntion>
      <Position>765</Position>
      <Original>Ala</Original>
      <Variation>Thr</Variation>
    </Muntion>
    <Muntion>
      <Position>814</Position>
      <Original>Ser</Original>
      <Variation>Asn</Variation>
    </Muntion>
    <Muntion>
      <Position>904</Position>
      <Original>Pro</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>913</Position>
      <Original>Pro</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>695</Position>
      <Original>Asp</Original>
      <Variation>Asn</Variation>
    </Muntion>
    <Muntion>
      <Position>904</Position>
      <Original>Pro</Original>
      <Variation>His</Variation>
    </Muntion>
    <Muntion>
      <Position>730</Position>
      <Original>Val</Original>
      <Variation>Met</Variation>
    </Muntion>
    <Muntion>
      <Position>559</Position>
      <Original>Cys</Original>
      <Variation>Tyr</Variation>
    </Muntion>
    <Muntion>
      <Position>871</Position>
      <Original>Arg</Original>
      <Variation>Gly</Variation>
    </Muntion>
    <Muntion>
      <Position>865</Position>
      <Original>Ser</Original>
      <Variation>Pro</Variation>
    </Muntion>
    <Muntion>
      <Position>752</Position>
      <Original>Arg</Original>
      <Variation>Gln</Variation>
    </Muntion>
    <Muntion>
      <Position>780</Position>
      <Original>Met</Original>
      <Variation>Ile</Variation>
    </Muntion>
    <Muntion>
      <Position>821</Position>
      <Original>Leu</Original>
      <Variation>Val</Variation>
    </Muntion>
    <Muntion>
      <Position>916</Position>
      <Original>Phe</Original>
      <Variation>Leu</Variation>
    </Muntion>
    <Muntion>
      <Position>746</Position>
      <Original>Val</Original>
      <Variation>Met</Variation>
    </Muntion>
    <Muntion>
      <Position>194</Position>
      <Original>Gln</Original>
      <Variation>Arg</Variation>
    </Muntion>
  </Mutation_List>
  <BioProcess_List>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of addition of phosphate groups to a molecule.</Detail>
      <Keyword>Positive regulation of phosphorylation</Keyword>
      <Ontology_ID>GO:0042327</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of integrins.</Detail>
      <Keyword>Negative regulation of integrin biosynthetic process</Keyword>
      <Ontology_ID>GO:0045720</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of cell death by apoptosis.</Detail>
      <Keyword>Negative regulation of apoptosis</Keyword>
      <Ontology_ID>GO:0043066</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the frequency, rate or extent of the synthesis of either RNA on a template of DNA or DNA on a template of RNA.</Detail>
      <Keyword>Regulation of transcription</Keyword>
      <Ontology_ID>GO:0045449</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of transcription from the RNA polymerase II promoter.</Detail>
      <Keyword>Positive regulation of transcription from RNA polymerase II promoter</Keyword>
      <Ontology_ID>GO:0045944</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The cellular synthesis of either RNA on a template of DNA or DNA on a template of RNA.</Detail>
      <Keyword>Transcription</Keyword>
      <Ontology_ID>GO:0006350</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A biological process that results in permanent cessation of all vital functions of a cell.</Detail>
      <Keyword>Cell death</Keyword>
      <Ontology_ID>GO:0008219</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The multiplication or reproduction of cells, resulting in the expansion of a cell population.</Detail>
      <Keyword>Cell proliferation</Keyword>
      <Ontology_ID>GO:0008283</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of transcription from the RNA polymerase III promoter.</Detail>
      <Keyword>Positive regulation of transcription from RNA polymerase III promoter</Keyword>
      <Ontology_ID>GO:0045945</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that mediates the transfer of information from one cell to another.</Detail>
      <Keyword>Cell-cell signaling</Keyword>
      <Ontology_ID>GO:0007267</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the rate or extent of cell proliferation.</Detail>
      <Keyword>Positive regulation of cell proliferation</Keyword>
      <Ontology_ID>GO:0008284</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The process in which a cell irreversibly increases in size over time by accretion and biosynthetic production of matter similar to that already present.</Detail>
      <Keyword>Cell growth</Keyword>
      <Ontology_ID>GO:0016049</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of activity of the transcription factor NF-kappaB.</Detail>
      <Keyword>Positive regulation of NF-kappaB transcription factor activity</Keyword>
      <Ontology_ID>GO:0051092</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process involved in the assembly of the RNA polymerase II preinitiation complex (PIC) at an RNA polymerase II promoter region of a DNA template, resulting in the subsequent synthesis of RNA from that promoter. The initiation phase includes PIC assembly and the formation of the first few bonds in the RNA chain, including abortive initiation, which occurs when the first few nucleotides are repeatedly synthesized and then released. Promoter clearance, or release, is the transition between the initiation and elongation phases of transcription.</Detail>
      <Keyword>Transcription initiation from RNA polymerase II promoter</Keyword>
      <Ontology_ID>GO:0006367</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of integrins.</Detail>
      <Keyword>Positive regulation of integrin biosynthetic process</Keyword>
      <Ontology_ID>GO:0045726</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The directed movement of substances (such as macromolecules, small molecules, ions) into, out of or within a cell, or between cells, or within a multicellular organism by means of some agent such as a transporter or pore.</Detail>
      <Keyword>Transport</Keyword>
      <Ontology_ID>GO:0006810</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the frequency, rate or extent of the directed movement of a protein to a specific location in the plasma membrane.</Detail>
      <Keyword>Regulation of establishment of protein localization in plasma membrane</Keyword>
      <Ontology_ID>GO:0090003</Ontology_ID>
    </BioProcess>
  </BioProcess_List>
  <PTM_List>
    <PTM>
      <Position>393</Position>
      <PTM_Type>Phosphotyrosine</PTM_Type>
    </PTM>
    <PTM>
      <Position>301</Position>
      <PTM_Type>Phosphothreonine</PTM_Type>
    </PTM>
    <PTM>
      <Position>81</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>650</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>534</Position>
      <PTM_Type>Phosphotyrosine</PTM_Type>
    </PTM>
    <PTM>
      <Position>346</Position>
      <PTM_Type>Phosphotyrosine</PTM_Type>
    </PTM>
    <PTM>
      <Position>307</Position>
      <PTM_Type>Phosphotyrosine</PTM_Type>
    </PTM>
    <PTM>
      <Position>915</Position>
      <PTM_Type>Phosphotyrosine</PTM_Type>
    </PTM>
    <PTM>
      <Position>363</Position>
      <PTM_Type>Phosphotyrosine</PTM_Type>
    </PTM>
    <PTM>
      <Position>267</Position>
      <PTM_Type>Phosphotyrosine</PTM_Type>
    </PTM>
    <PTM>
      <Position>223</Position>
      <PTM_Type>Phosphotyrosine</PTM_Type>
    </PTM>
    <PTM>
      <Position>300</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>362</Position>
      <PTM_Type>Phosphotyrosine</PTM_Type>
    </PTM>
    <PTM>
      <Position>357</Position>
      <PTM_Type>Phosphotyrosine</PTM_Type>
    </PTM>
    <PTM>
      <Position>551</Position>
      <PTM_Type>Phosphotyrosine</PTM_Type>
    </PTM>
  </PTM_List>
  <Molecule_Seq>
    <Protein_Seq>MEVQLGLGRVYPRPPSKTYRGAFQNLFQSVREVIQNPGPRHPEAASAAPPGASLLLLQQQQQQQQQQQQQQQQQQQQQETSPRQQQQQQGEDGSPQAHRRGPTGYLVLDEEQQPSQPQSALECHPERGCVPEPGAAVAASKGLPQQLPAPPDEDDSAAPSTLSLLGPTFPGLSSCSADLKDILSEASTMQLLQQQQQEAVSEGSSSGRAREASGAPTSSKDNYLGGTSTISDNAKELCKAVSVSMGLGVEALEHLSPGEQLRGDCMYAPLLGVPPAVRPTPCAPLAECKGSLLDDSAGKSTEDTAEYSPFKGGYTKGLEGESLGCSGSAAAGSSGTLELPSTLSLYKSGALDEAAAYQSRDYYNFPLALAGPPPPPPPPHPHARIKLENPLDYGSAWAAAAAQCRYGDLASLHGAGAAGPGSGSPSAAASSSWHTLFTAEEGQLYGPCGGGGGGGGGGGGGGGGGGGGGGGGEAGAVAPYGYTRPPQGLAGQESDFTAPDVWYPGGMVSRVPYPSPTCVKSEMGPWMDSYSGPYGDMRLETARDHVLPIDYYFPPQKTCLICGDEASGCHYGALTCGSCKVFFKRAAEGKQKYLCASRNDCTIDKFRRKNCPSCRLRKCYEAGMTLGARKLKKLGNLKLQEEGEASSTTSPTEETTQKLTVSHIEGYECQPIFLNVLEAIEPGVVCAGHDNNQPDSFAALLSSLNELGERQLVHVVKWAKALPGFRNLHVDDQMAVIQYSWMGLMVFAMGWRSFTNVNSRMLYFAPDLVFNEYRMHKSRMYSQCVRMRHLSQEFGWLQITPQEFLCMKALLLFSIIPVDGLKNQKFFDELRMNYIKELDRIIACKRKNPTSCSRRFYQLTKLLDSVQPIARELHQFTFDLLIKSHMVSVDFPEMMAEIISVQVPKILSGKVKPIYFHTQ</Protein_Seq>
    <DNA_Seq>CGAGATCCCGGGGAGCCAGCTTGCTGGGAGAGCGGGACGGTCCGGAGCAAGCCCAGAGGCAGAGGAGGCGACAGAGGGAAAAAGGGCCGAGCTAGCCGCTCCAGTGCTGTACAGGAGCCGAAGGGACGCACCACGCCAGCCCCAGCCCGGCTCCAGCGACAGCCAACGCCTCTTGCAGCGCGGCGGCTTCGAAGCCGCCGCCCGGAGCTGCCCTTTCCTCTTCGGTGAAGTTTTTAAAAGCTGCTAAAGACTCGGAGGAAGCAAGGAAAGTGCCTGGTAGGACTGACGGCTGCCTTTGTCCTCCTCCTCTCCACCCCGCCTCCCCCCACCCTGCCTTCCCCCCCTCCCCCGTCTTCTCTCCCGCAGCTGCCTCAGTCGGCTACTCTCAGCCAACCCCCCTCACCACCCTTCTCCCCACCCGCCCCCCCGCCCCCGTCGGCCCAGCGCTGCCAGCCCGAGTTTGCAGAGAGGTAACTCCCTTTGGCTGCGAGCGGGCGAGCTAGCTGCACATTGCAAAGAAGGCTCTTAGGAGCCAGGCGACTGGGGAGCGGCTTCAGCACTGCAGCCACGACCCGCCTGGTTAGGCTGCACGCGGAGAGAACCCTCTGTTTTCCCCCACTCTCTCTCCACCTCCTCCTGCCTTCCCCACCCCGAGTGCGGAGCCAGAGATCAAAAGATGAAAAGGCAGTCAGGTCTTCAGTAGCCAAAAAACAAAACAAACAAAAACAAAAAAGCCGAAATAAAAGAAAAAGATAATAACTCAGTTCTTATTTGCACCTACTTCAGTGGACACTGAATTTGGAAGGTGGAGGATTTTGTTTTTTTCTTTTAAGATCTGGGCATCTTTTGAATCTACCCTTCAAGTATTAAGAGACAGACTGTGAGCCTAGCAGGGCAGATCTTGTCCACCGTGTGTCTTCTTCTGCACGAGACTTTGAGGCTGTCAGAGCGCTTTTTGCGTGGTTGCTCCCGCAAGTTTCCTTCTCTGGAGCTTCCCGCAGGTGGGCAGCTAGCTGCAGCGACTACCGCATCATCACAGCCTGTTGAACTCTTCTGAGCAAGAGAAGGGGAGGCGGGGTAAGGGAAGTAGGTGGAAGATTCAGCCAAGCTCAAGGATGGAAGTGCAGTTAGGGCTGGGAAGGGTCTACCCTCGGCCGCCGTCCAAGACCTACCGAGGAGCTTTCCAGAATCTGTTCCAGAGCGTGCGCGAAGTGATCCAGAACCCGGGCCCCAGGCACCCAGAGGCCGCGAGCGCAGCACCTCCCGGCGCCAGTTTGCTGCTGCTGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAAGAGACTAGCCCCAGGCAGCAGCAGCAGCAGCAGGGTGAGGATGGTTCTCCCCAAGCCCATCGTAGAGGCCCCACAGGCTACCTGGTCCTGGATGAGGAACAGCAACCTTCACAGCCGCAGTCGGCCCTGGAGTGCCACCCCGAGAGAGGTTGCGTCCCAGAGCCTGGAGCCGCCGTGGCCGCCAGCAAGGGGCTGCCGCAGCAGCTGCCAGCACCTCCGGACGAGGATGACTCAGCTGCCCCATCCACGTTGTCCCTGCTGGGCCCCACTTTCCCCGGCTTAAGCAGCTGCTCCGCTGACCTTAAAGACATCCTGAGCGAGGCCAGCACCATGCAACTCCTTCAGCAACAGCAGCAGGAAGCAGTATCCGAAGGCAGCAGCAGCGGGAGAGCGAGGGAGGCCTCGGGGGCTCCCACTTCCTCCAAGGACAATTACTTAGGGGGCACTTCGACCATTTCTGACAACGCCAAGGAGTTGTGTAAGGCAGTGTCGGTGTCCATGGGCCTGGGTGTGGAGGCGTTGGAGCATCTGAGTCCAGGGGAACAGCTTCGGGGGGATTGCATGTACGCCCCACTTTTGGGAGTTCCACCCGCTGTGCGTCCCACTCCTTGTGCCCCATTGGCCGAATGCAAAGGTTCTCTGCTAGACGACAGCGCAGGCAAGAGCACTGAAGATACTGCTGAGTATTCCCCTTTCAAGGGAGGTTACACCAAAGGGCTAGAAGGCGAGAGCCTAGGCTGCTCTGGCAGCGCTGCAGCAGGGAGCTCCGGGACACTTGAACTGCCGTCTACCCTGTCTCTCTACAAGTCCGGAGCACTGGACGAGGCAGCTGCGTACCAGAGTCGCGACTACTACAACTTTCCACTGGCTCTGGCCGGACCGCCGCCCCCTCCGCCGCCTCCCCATCCCCACGCTCGCATCAAGCTGGAGAACCCGCTGGACTACGGCAGCGCCTGGGCGGCTGCGGCGGCGCAGTGCCGCTATGGGGACCTGGCGAGCCTGCATGGCGCGGGTGCAGCGGGACCCGGTTCTGGGTCACCCTCAGCCGCCGCTTCCTCATCCTGGCACACTCTCTTCACAGCCGAAGAAGGCCAGTTGTATGGACCGTGTGGTGGTGGTGGGGGTGGTGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGAGGCGGGAGCTGTAGCCCCCTACGGCTACACTCGGCCCCCTCAGGGGCTGGCGGGCCAGGAAAGCGACTTCACCGCACCTGATGTGTGGTACCCTGGCGGCATGGTGAGCAGAGTGCCCTATCCCAGTCCCACTTGTGTCAAAAGCGAAATGGGCCCCTGGATGGATAGCTACTCCGGACCTTACGGGGACATGCGTTTGGAGACTGCCAGGGACCATGTTTTGCCCATTGACTATTACTTTCCACCCCAGAAGACCTGCCTGATCTGTGGAGATGAAGCTTCTGGGTGTCACTATGGAGCTCTCACATGTGGAAGCTGCAAGGTCTTCTTCAAAAGAGCCGCTGAAGGGAAACAGAAGTACCTGTGCGCCAGCAGAAATGATTGCACTATTGATAAATTCCGAAGGAAAAATTGTCCATCTTGTCGTCTTCGGAAATGTTATGAAGCAGGGATGACTCTGGGAGCCCGGAAGCTGAAGAAACTTGGTAATCTGAAACTACAGGAGGAAGGAGAGGCTTCCAGCACCACCAGCCCCACTGAGGAGACAACCCAGAAGCTGACAGTGTCACACATTGAAGGCTATGAATGTCAGCCCATCTTTCTGAATGTCCTGGAAGCCATTGAGCCAGGTGTAGTGTGTGCTGGACACGACAACAACCAGCCCGACTCCTTTGCAGCCTTGCTCTCTAGCCTCAATGAACTGGGAGAGAGACAGCTTGTACACGTGGTCAAGTGGGCCAAGGCCTTGCCTGGCTTCCGCAACTTACACGTGGACGACCAGATGGCTGTCATTCAGTACTCCTGGATGGGGCTCATGGTGTTTGCCATGGGCTGGCGATCCTTCACCAATGTCAACTCCAGGATGCTCTACTTCGCCCCTGATCTGGTTTTCAATGAGTACCGCATGCACAAGTCCCGGATGTACAGCCAGTGTGTCCGAATGAGGCACCTCTCTCAAGAGTTTGGATGGCTCCAAATCACCCCCCAGGAATTCCTGTGCATGAAAGCACTGCTACTCTTCAGCATTATTCCAGTGGATGGGCTGAAAAATCAAAAATTCTTTGATGAACTTCGAATGAACTACATCAAGGAACTCGATCGTATCATTGCATGCAAAAGAAAAAATCCCACATCCTGCTCAAGACGCTTCTACCAGCTCACCAAGCTCCTGGACTCCGTGCAGCCTATTGCGAGAGAGCTGCATCAGTTCACTTTTGACCTGCTAATCAAGTCACACATGGTGAGCGTGGACTTTCCGGAAATGATGGCAGAGATCATCTCTGTGCAAGTGCCCAAGATCCTTTCTGGGAAAGTCAAGCCCATCTATTTCCACACCCAGTGAAGCATTGGAAACCCTATTTCCCCACCCCAGCTCATGCCCCCTTTCAGATGTCTTCTGCCTGTTATAACTCTGCACTACTCCTCTGCAGTGCCTTGGGGAATTTCCTCTATTGATGTACAGTCTGTCATGAACATGTTCCTGAATTCTATTTGCTGGGCTTTTTTTTTCTCTTTCTCTCCTTTCTTTTTCTTCTTCCCTCCCTATCTAACCCTCCCATGGCACCTTCAGACTTTGCTTCCCATTGTGGCTCCTATCTGTGTTTTGAATGGTGTTGTATGCCTTTAAATCTGTGATGATCCTCATATGGCCCAGTGTCAAGTTGTGCTTGTTTACAGCACTACTCTGTGCCAGCCACACAAACGTTTACTTATCTTATGCCACGGGAAGTTTAGAGAGCTAAGATTATCTGGGGAAATCAAAACAAAAACAAGCAAACAAAAAAAAAAAGCAAAAACAAAACAAAAAATAAGCCAAAAAACCTTGCTAGTGTTTTTTCCTCAAAAATAAATAAATAAATAAATAAATACGTACATACATACACACATACATACAAACATATAGAAATCCCCAAAGAGGCCAATAGTGACGAGAAGGTGAAAATTGCAGGCCCATGGGGAGTTACTGATTTTTTCATCTCCTCCCTCCACGGGAGACTTTATTTTCTGCCAATGGCTATTGCCATTAGAGGGCAGAGTGACCCCAGAGCTGAGTTGGGCAGGGGGGTGGACAGAGAGGAGAGGACAAGGAGGGCAATGGAGCATCAGTACCTGCCCACAGCCTTGGTCCCTGGGGGCTAGACTGCTCAACTGTGGAGCAATTCATTATACTGAAAATGTGCTTGTTGTTGAAAATTTGTCTGCATGTTAATGCCTCACCCCCAAACCCTTTTCTCTCTCACTCTCTGCCTCCAACTTCAGATTGACTTTCAATAGTTTTTCTAAGACCTTTGAACTGAATGTTCTCTTCAGCCAAAACTTGGCGACTTCCACAGAAAAGTCTGACCACTGAGAAGAAGGAGAGCAGAGATTTAACCCTTTGTAAGGCCCCATTTGGATCCAGGTCTGCTTTCTCATGTGTGAGTCAGGGAGGAGCTGGAGCCAGAGGAGAAGAAAATGATAGCTTGGCTGTTCTCCTGCTTAGGACACTGACTGAATAGTTAAACTCTCACTGCCACTACCTTTTCCCCACCTTTAAAAGACCTGAATGAAGTTTTCTGCCAAACTCCGTGAAGCCACAAGCACCTTATGTCCTCCCTTCAGTGTTTTGTGGGCCTGAATTTCATCACACTGCATTTCAGCCATGGTCATCAAGCCTGTTTGCTTCTTTTGGGCATGTTCACAGATTCTCTGTTAAGAGCCCCCACCACCAAGAAGGTTAGCAGGCCAACAGCTCTGACATCTATCTGTAGATGCCAGTAGTCACAAAGATTTCTTACCAACTCTCAGATCGCTGGAGCCCTTAGACAAACTGGAAAGAAGGCATCAAAGGGATCAGGCAAGCTGGGCGTCTTGCCCTTGTCCCCCAGAGATGATACCCTCCCAGCAAGTGGAGAAGTTCTCACTTCCTTCTTTAGAGCAGCTAAAGGGGCTACCCAGATCAGGGTTGAAGAGAAAACTCAATTACCAGGGTGGGAAGAATGAAGGCACTAGAACCAGAAACCCTGCAAATGCTCTTCTTGTCACCCAGCATATCCACCTGCAGAAGTCATGAGAAGAGAGAAGGAACAAAGAGGAGACTCTGACTACTGAATTAAAATCTTCAGCGGCAAAGCCTAAAGCCAGATGGACACCATCTGGTGAGTTTACTCATCATCCTCCTCTGCTGCTGATTCTGGGCTCTGACATTGCCCATACTCACTCAGATTCCCCACCTTTGTTGCTGCCTCTTAGTCAGAGGGAGGCCAAACCATTGAGACTTTCTACAGAACCATGGCTTCTTTCGGAAAGGTCTGGTTGGTGTGGCTCCAATACTTTGCCACCCATGAACTCAGGGTGTGCCCTGGGACACTGGTTTTATATAGTCTTTTGGCACACCTGTGTTCTGTTGACTTCGTTCTTCAAGCCCAAGTGCAAGGGAAAATGTCCACCTACTTTCTCATCTTGGCCTCTGCCTCCTTACTTAGCTCTTAATCTCATCTGTTGAACTCAAGAAATCAAGGGCCAGTCATCAAGCTGCCCATTTTAATTGATTCACTCTGTTTGTTGAGAGGATAGTTTCTGAGTGACATGATATGATCCACAAGGGTTTCCTTCCCTGATTTCTGCATTGATATTAATAGCCAAACGAACTTCAAAACAGCTTTAAATAACAAGGGAGAGGGGAACCTAAGATGAGTAATATGCCAATCCAAGACTGCTGGAGAAAACTAAAGCTGACAGGTTCCCTTTTTGGGGTGGGATAGACATGTTCTGGTTTTCTTTATTATTACACAATCTGGCTCATGTACAGGATCACTTTTAGCTGTTTTAAACAGAAAAAAATATCCACCACTCTTTTCAGTTACACTAGGTTACATTTTAATAGGTCCTTTACATCTGTTTTGGAATGATTTTCATCTTTTGTGATACACAGATTGAATTATATCATTTTCATATCTCTCCTTGTAAATACTAGAAGCTCTCCTTTACATTTCTCTATCAAATTTTTCATCTTTATGGGTTTCCCAATTGTGACTCTTGTCTTCATGAATATATGTTTTTCATTTGCAAAAGCCAAAAATCAGTGAAACAGCAGTGTAATTAAAAGCAACAACTGGATTACTCCAAATTTCCAAATGACAAAACTAGGGAAAAATAGCCTACACAAGCCTTTAGGCCTACTCTTTCTGTGCTTGGGTTTGAGTGAACAAAGGAGATTTTAGCTTGGCTCTGTTCTCCCATGGATGAAAGGAGGAGGATTTTTTTTTTCTTTTGGCCATTGATGTTCTAGCCAATGTAATTGACAGAAGTCTCATTTTGCATGCGCTCTGCTCTACAAACAGAGTTGGTATGGTTGGTATACTGTACTCACCTGTGAGGGACTGGCCACTCAGACCCACTTAGCTGGTGAGCTAGAAGATGAGGATCACTCACTGGAAAAGTCACAAGGACCATCTCCAAACAAGTTGGCAGTGCTCGATGTGGACGAAGAGTGAGGAAGAGAAAAAGAAGGAGCACCAGGGAGAAGGCTCCGTCTGTGCTGGGCAGCAGACAGCTGCCAGGATCACGAACTCTGTAGTCAAAGAAAAGAGTCGTGTGGCAGTTTCAGCTCTCGTTCATTGGGCAGCTCGCCTAGGCCCAGCCTCTGAGCTGACATGGGAGTTGTTGGATTCTTTGTTTCATAGCTTTTTCTATGCCATAGGCAATATTGTTGTTCTTGGAAAGTTTATTATTTTTTTAACTCCCTTACTCTGAGAAAGGGATATTTTGAAGGACTGTCATATATCTTTGAAAAAAGAAAATCTGTAATACATATATTTTTATGTATGTTCACTGGCACTAAAAAATATAGAGAGCTTCATTCTGTCCTTTGGGTAGTTGCTGAGGTAATTGTCCAGGTTGAAAAATAATGTGCTGATGCTAGAGTCCCTCTCTGTCCATACTCTACTTCTAAATACATATAGGCATACATAGCAAGTTTTATTTGACTTGTACTTTAAGAGAAAATATGTCCACCATCCACATGATGCACAAATGAGCTAACATTGAGCTTCAAGTAGCTTCTAAGTGTTTGTTTCATTAGGCACAGCACAGATGTGGCCTTTCCCCCCTTCTCTCCCTTGATATCTGGCAGGGCATAAAGGCCCAGGCCACTTCCTCTGCCCCTTCCCAGCCCTGCACCAAAGCTGCATTTCAGGAGACTCTCTCCAGACAGCCCAGTAACTACCCGAGCATGGCCCCTGCATAGCCCTGGAAAAATAAGAGGCTGACTGTCTACGAATTATCTTGTGCCAGTTGCCCAGGTGAGAGGGCACTGGGCCAAGGGAGTGGTTTTCATGTTTGACCCACTACAAGGGGTCATGGGAATCAGGAATGCCAAAGCACCAGATCAAATCCAAAACTTAAAGTCAAAATAAGCCATTCAGCATGTTCAGTTTCTTGGAAAAGGAAGTTTCTACCCCTGATGCCTTTGTAGGCAGATCTGTTCTCACCATTAATCTTTTTGAAAATCTTTTAAAGCAGTTTTTAAAAAGAGAGATGAAAGCATCACATTATATAACCAAAGATTACATTGTACCTGCTAAGATACCAAAATTCATAAGGGCAGGGGGGGAGCAAGCATTAGTGCCTCTTTGATAAGCTGTCCAAAGACAGACTAAAGGACTCTGCTGGTGACTGACTTATAAGAGCTTTGTGGGTTTTTTTTTCCCTAATAATATACATGTTTAGAAGAATTGAAAATAATTTCGGGAAAATGGGATTATGGGTCCTTCACTAAGTGATTTTATAAGCAGAACTGGCTTTCCTTTTCTCTAGTAGTTGCTGAGCAAATTGTTGAAGCTCCATCATTGCATGGTTGGAAATGGAGCTGTTCTTAGCCACTGTGTTTGCTAGTGCCCATGTTAGCTTATCTGAAGATGTGAAACCCTTGCTGATAAGGGAGCATTTAAAGTACTAGATTTTGCACTAGAGGGACAGCAGGCAGAAATCCTTATTTCTGCCCACTTTGGATGGCACAAAAAGTTATCTGCAGTTGAAGGCAGAAAGTTGAAATACATTGTAAATGAATATTTGTATCCATGTTTCAAAATTGAAATATATATATATATATATATATATATATATATATATATATAGTGTGTGTGTGTGTTCTGATAGCTTTAACTTTCTCTGCATCTTTATATTTGGTTCCAGATCACACCTGATGCCATGTACTTGTGAGAGAGGATGCAGTTTTGTTTTGGAAGCTCTCTCAGAACAAACAAGACACCTGGATTGATCAGTTAACTAAAAGTTTTCTCCCCTATTGGGTTTGACCCACAGGTCCTGTGAAGGAGCAGAGGGATAAAAAGAGTAGAGGACATGATACATTGTACTTTACTAGTTCAAGACAGATGAATGTGGAAAGCATAAAAACTCAATGGAACTGACTGAGATTTACCACAGGGAAGGCCCAAACTTGGGGCCAAAAGCCTACCCAAGTGATTGACCAGTGGCCCCCTAATGGGACCTGAGCTGTTGGAAGAAGAGAACTGTTCCTTGGTCTTCACCATCCTTGTGAGAGAAGGGCAGTTTCCTGCATTGGAACCTGGAGCAAGCGCTCTATCTTTCACACAAATTCCCTCACCTGAGATTGAGGTGCTCTTGTTACTGGGTGTCTGTGTGCTGTAATTCTGGTTTTGGATATGTTCTGTAAAGATTTTGACAAATGAAAATGTGTTTTTCTCTGTTAAAACTTGTCAGAGTACTAGAAGTTGTATCTCTGTAGGTGCAGGTCCATTTCTGCCCACAGGTAGGGTGTTTTTCTTTGATTAAGAGATTGACACTTCTGTTGCCTAGGACCTCCCAACTCAACCATTTCTAGGTGAAGGCAGAAAAATCCACATTAGTTACTCCTCTTCAGACATTTCAGCTGAGATAACAAATCTTTTGGAATTTTTTCACCCATAGAAAGAGTGGTAGATATTTGAATTTAGCAGGTGGAGTTTCATAGTAAAAACAGCTTTTGACTCAGCTTTGATTTATCCTCATTTGATTTGGCCAGAAAGTAGGTAATATGCATTGATTGGCTTCTGATTCCAATTCAGTATAGCAAGGTGCTAGGTTTTTTCCTTTCCCCACCTGTCTCTTAGCCTGGGGAATTAAATGAGAAGCCTTAGAATGGGTGGCCCTTGTGACCTGAAACACTTCCCACATAAGCTACTTAACAAGATTGTCATGGAGCTGCAGATTCCATTGCCCACCAAAGACTAGAACACACACATATCCATACACCAAAGGAAAGACAATTCTGAAATGCTGTTTCTCTGGTGGTTCCCTCTCTGGCTGCTGCCTCACAGTATGGGAACCTGTACTCTGCAGAGGTGACAGGCCAGATTTGCATTATCTCACAACCTTAGCCCTTGGTGCTAACTGTCCTACAGTGAAGTGCCTGGGGGGTTGTCCTATCCCATAAGCCACTTGGATGCTGACAGCAGCCACCATCAGAATGACCCACGCAAAAAAAAGAAAAAAAAAATTAAAAAGTCCCCTCACAACCCAGTGACACCTTTCTGCTTTCCTCTAGACTGGAACATTGATTAGGGAGTGCCTCAGACATGACATTCTTGTGCTGTCCTTGGAATTAATCTGGCAGCAGGAGGGAGCAGACTATGTAAACAGAGATAAAAATTAATTTTCAATATTGAAGGAAAAAAGAAATAAGAAGAGAGAGAGAAAGAAAGCATCACACAAAGATTTTCTTAAAAGAAACAATTTTGCTTGAAATCTCTTTAGATGGGGCTCATTTCTCACGGTGGCACTTGGCCTCCACTGGGCAGCAGGACCAGCTCCAAGCGCTAGTGTTCTGTTCTCTTTTTGTAATCTTGGAATCTTTTGTTGCTCTAAATACAATTAAAAATGGCAGAAACTTGTTTGTTGGACTACATGTGTGACTTTGGGTCTGTCTCTGCCTCTGCTTTCAGAAATGTCATCCATTGTGTAAAATATTGGCTTACTGGTCTGCCAGCTAAAACTTGGCCACATCCCCTGTTATGGCTGCAGGATCGAGTTATTGTTAACAAAGAGACCCAAGAAAAGCTGCTAATGTCCTCTTATCATTGTTGTTAATTTGTTAAAACATAAAGAAATCTAAAATTTCAAAAAA</DNA_Seq>
  </Molecule_Seq>
  <Tissuelocal_List>
    <TissueLocal>
      <TissueLocal>Heart</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Skeletal muscle</TissueLocal>
    </TissueLocal>
  </Tissuelocal_List>
  <CellLocal_List>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Nucleus</CellLocal>
      <Ontology_ID>GO:0005634</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Nuclear chromatin</CellLocal>
      <Ontology_ID>GO:0000790</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Cytoplasm</CellLocal>
      <Ontology_ID>GO:0005737</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Nucleoplasm</CellLocal>
      <Ontology_ID>GO:0005654</Ontology_ID>
    </AsdMacromoleculeCelllocal>
  </CellLocal_List>
  <Gene>
    <Gene_Name>AR</Gene_Name>
    <Gene_Alias>DHTR; NR3C4</Gene_Alias>
    <Gene_ID>367</Gene_ID>
    <Genbank_ACCN>NM_000044</Genbank_ACCN>
    <Protein_ACCN>NP_000035</Protein_ACCN>
    <HGNC_ID>644</HGNC_ID>
    <Gene_URL>http://www.ncbi.nlm.nih.gov/gene/367</Gene_URL>
    <EMBL_ID>ENSG00000169083</EMBL_ID>
  </Gene>
  <PPI_List>
    <PPI>
      <Uniprot_ID>Q9UBS8</Uniprot_ID>
      <Gene_Name>RNF14</Gene_Name>
      <EBI_ID>EBI-2130308</EBI_ID>
      <PPI_EBI_URL>EBI-608057,EBI-2130308</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q06830</Uniprot_ID>
      <Gene_Name>PRDX1</Gene_Name>
      <EBI_ID>EBI-353193</EBI_ID>
      <PPI_EBI_URL>EBI-608057,EBI-353193</PPI_EBI_URL>
      <Experiment_Number>3</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q15596</Uniprot_ID>
      <Gene_Name>NCOA2</Gene_Name>
      <EBI_ID>EBI-81236</EBI_ID>
      <PPI_EBI_URL>EBI-608057,EBI-81236</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P56524</Uniprot_ID>
      <Gene_Name>HDAC4</Gene_Name>
      <EBI_ID>EBI-308629</EBI_ID>
      <PPI_EBI_URL>EBI-608057,EBI-308629</PPI_EBI_URL>
      <Experiment_Number>4</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q14686</Uniprot_ID>
      <Gene_Name>NCOA6</Gene_Name>
      <EBI_ID>EBI-78670</EBI_ID>
      <PPI_EBI_URL>EBI-608057,EBI-78670</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P11308</Uniprot_ID>
      <Gene_Name>ERG</Gene_Name>
      <EBI_ID>EBI-79704</EBI_ID>
      <PPI_EBI_URL>EBI-608057,EBI-79704</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P20711</Uniprot_ID>
      <Gene_Name>DDC</Gene_Name>
      <EBI_ID>EBI-1632155</EBI_ID>
      <PPI_EBI_URL>EBI-608057,EBI-1632155</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P63165</Uniprot_ID>
      <Gene_Name>SUMO1</Gene_Name>
      <EBI_ID>EBI-80140</EBI_ID>
      <PPI_EBI_URL>EBI-608057,EBI-80140</PPI_EBI_URL>
      <Experiment_Number>7</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>O95251</Uniprot_ID>
      <Gene_Name>KAT7</Gene_Name>
      <EBI_ID>EBI-473199</EBI_ID>
      <PPI_EBI_URL>EBI-608057,EBI-473199</PPI_EBI_URL>
      <Experiment_Number>5</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q9UER7</Uniprot_ID>
      <Gene_Name>DAXX</Gene_Name>
      <EBI_ID>EBI-77321</EBI_ID>
      <PPI_EBI_URL>EBI-608057,EBI-77321</PPI_EBI_URL>
      <Experiment_Number>5</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q15652</Uniprot_ID>
      <Gene_Name>JMJD1C</Gene_Name>
      <EBI_ID>EBI-1224969</EBI_ID>
      <PPI_EBI_URL>EBI-608057,EBI-1224969</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q00987</Uniprot_ID>
      <Gene_Name>MDM2</Gene_Name>
      <EBI_ID>EBI-389668</EBI_ID>
      <PPI_EBI_URL>EBI-608057,EBI-389668</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P35222</Uniprot_ID>
      <Gene_Name>CTNNB1</Gene_Name>
      <EBI_ID>EBI-491549</EBI_ID>
      <PPI_EBI_URL>EBI-608057,EBI-491549</PPI_EBI_URL>
      <Experiment_Number>4</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q92793</Uniprot_ID>
      <Gene_Name>CREBBP</Gene_Name>
      <EBI_ID>EBI-81215</EBI_ID>
      <PPI_EBI_URL>EBI-608057,EBI-81215</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q16665</Uniprot_ID>
      <Gene_Name>HIF1A</Gene_Name>
      <EBI_ID>EBI-447269</EBI_ID>
      <PPI_EBI_URL>EBI-608057,EBI-447269</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q9R1E0</Uniprot_ID>
      <Gene_Name>Foxo1</Gene_Name>
      <EBI_ID>EBI-1371343</EBI_ID>
      <PPI_EBI_URL>EBI-608057,EBI-1371343</PPI_EBI_URL>
      <Experiment_Number>4</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q9Y252</Uniprot_ID>
      <Gene_Name>RNF6</Gene_Name>
      <EBI_ID>EBI-2341483</EBI_ID>
      <PPI_EBI_URL>EBI-608057,EBI-2341483</PPI_EBI_URL>
      <Experiment_Number>10</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q99497</Uniprot_ID>
      <Gene_Name>PARK7</Gene_Name>
      <EBI_ID>EBI-1164361</EBI_ID>
      <PPI_EBI_URL>EBI-608057,EBI-1164361</PPI_EBI_URL>
      <Experiment_Number>6</Experiment_Number>
    </PPI>
  </PPI_List>
  <Disease_List>
    <Disease>
      <Disease_Name>Transsexualism</Disease_Name>
      <Disease_Detail>Transsexualism</Disease_Detail>
      <Disease_DB>TRN007</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/transsexualism?search=AR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Gender Identity Disorder</Disease_Name>
      <Disease_Detail>Gender Identity Disorder</Disease_Detail>
      <Disease_DB>GND002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/gender_identity_disorder?search=AR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Prostate Cancer</Disease_Name>
      <Disease_Detail>Prostate Cancer</Disease_Detail>
      <Disease_DB>PRS040</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/prostate_cancer?search=AR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Androgenetic Alopecia</Disease_Name>
      <Disease_Detail>Androgenetic Alopecia</Disease_Detail>
      <Disease_DB>AND009</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/androgenetic_alopecia?search=AR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Prostate Cancer, Progression of</Disease_Name>
      <Disease_Detail>Prostate Cancer</Disease_Detail>
      <Disease_DB>PRS085</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/prostate_cancer_progression_of?search=AR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Cryptorchidism</Disease_Name>
      <Disease_Detail>Cryptorchidism</Disease_Detail>
      <Disease_DB>CRY002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/cryptorchidism?search=AR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Gastric Neuroendocrine Neoplasm</Disease_Name>
      <Disease_Detail>Gastric Neuroendocrine Neoplasm</Disease_Detail>
      <Disease_DB>GST004</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/gastric_neuroendocrine_neoplasm?search=AR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hypospadias</Disease_Name>
      <Disease_Detail>Hypospadias</Disease_Detail>
      <Disease_DB>HYP040</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hypospadias?search=AR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Isolated Micropenis</Disease_Name>
      <Disease_Detail>Isolated Micropenis</Disease_Detail>
      <Disease_DB>ISL069</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/isolated_micropenis?search=AR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Male Breast Cancer</Disease_Name>
      <Disease_Detail>Breast Cancer</Disease_Detail>
      <Disease_DB>MLB002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/male_breast_cancer?search=AR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Prostate Cancer 4</Disease_Name>
      <Disease_Detail>Prostate Cancer</Disease_Detail>
      <Disease_DB>PRS105</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/prostate_cancer_4?search=AR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Partial Androgen Insensitivity Syndrome</Disease_Name>
      <Disease_Detail>Partial Androgen Insensitivity Syndrome</Disease_Detail>
      <Disease_DB>PRT092</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/partial_androgen_insensitivity_syndrome?search=AR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Spermatogenesis Arrest</Disease_Name>
      <Disease_Detail>Spermatogenesis Arrest</Disease_Detail>
      <Disease_DB>SPR027</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/spermatogenesis_arrest?search=AR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Prostate Cancer, Hereditary, 5</Disease_Name>
      <Disease_Detail>Prostate Cancer</Disease_Detail>
      <Disease_DB>PRS079</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/prostate_cancer_hereditary_5?search=AR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>X-Linked Spinal-Bulbar Muscle Atrophy</Disease_Name>
      <Disease_Detail>X-Linked Spinal-Bulbar Muscle Atrophy</Disease_Detail>
      <Disease_DB>XLN009</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/x_linked_spinal_bulbar_muscle_atrophy?search=AR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hypospadias 1, X-Linked</Disease_Name>
      <Disease_Detail>Hypospadias</Disease_Detail>
      <Disease_DB>HYP284</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hypospadias_1_x_linked?search=AR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Muscular Atrophy</Disease_Name>
      <Disease_Detail>Muscular Atrophy</Disease_Detail>
      <Disease_DB>MSC003</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/muscular_atrophy?search=AR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Oligospermia</Disease_Name>
      <Disease_Detail>Oligospermia</Disease_Detail>
      <Disease_DB>OLG001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/oligospermia?search=AR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Prostate Cancer 3</Disease_Name>
      <Disease_Detail>Prostate Cancer</Disease_Detail>
      <Disease_DB>PRS104</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/prostate_cancer_3?search=AR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hermaphroditism</Disease_Name>
      <Disease_Detail>Hermaphroditism</Disease_Detail>
      <Disease_DB>HRM002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hermaphroditism?search=AR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Complete Androgen Insensitivity Syndrome</Disease_Name>
      <Disease_Detail>Complete Androgen Insensitivity Syndrome</Disease_Detail>
      <Disease_DB>CMP034</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/complete_androgen_insensitivity_syndrome?search=AR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Kennedy's Disease</Disease_Name>
      <Disease_Detail>Kennedy's Disease</Disease_Detail>
      <Disease_DB>KNN001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/kennedys_disease?search=AR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Androgen Insensitivity Syndrome</Disease_Name>
      <Disease_Detail>Androgen Insensitivity Syndrome</Disease_Detail>
      <Disease_DB>AND002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/androgen_insensitivity_syndrome?search=AR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Adenosarcoma</Disease_Name>
      <Disease_Detail>Adenosarcoma</Disease_Detail>
      <Disease_DB>ADN020</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/adenosarcoma?search=AR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Germ Cell Cancer</Disease_Name>
      <Disease_Detail>Germ Cell Cancer</Disease_Detail>
      <Disease_DB>GRM005</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/germ_cell_cancer?search=AR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Withdrawal Disorder</Disease_Name>
      <Disease_Detail>Withdrawal Disorder</Disease_Detail>
      <Disease_DB>WTH001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/withdrawal_disorder?search=AR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Vaginitis</Disease_Name>
      <Disease_Detail>Vaginitis</Disease_Detail>
      <Disease_DB>VGN023</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/vaginitis?search=AR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Mammary Paget's Disease</Disease_Name>
      <Disease_Detail>Mammary Paget's Disease</Disease_Detail>
      <Disease_DB>MMM001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/mammary_pagets_disease?search=AR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Breast Cancer</Disease_Name>
      <Disease_Detail>Breast Cancer</Disease_Detail>
      <Disease_DB>BRS047</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/breast_cancer?search=AR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Prostate Cancer, Somatic</Disease_Name>
      <Disease_Detail>Prostate Cancer</Disease_Detail>
      <Disease_DB>PRS065</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/prostate_cancer_somatic?search=AR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hemangioma</Disease_Name>
      <Disease_Detail>Hemangioma</Disease_Detail>
      <Disease_DB>HMN010</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hemangioma?search=AR#related_genes</Disease_URL>
    </Disease>
  </Disease_List>
  <PDB_List>
    <PDB>
      <PDB_Title>HUMAN ANDROGEN RECEPTOR LIGAND BINDING IN COMPLEX WITH THE LIGAND METRIBOLONE (R1881)</PDB_Title>
      <PDB_ID>1E3G</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1E3G</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural Evidence for Ligand Specificity in the Binding Domain of the Human Androgen Receptor. Implications for Pathogenic Gene Mutations</PubMed_Title>
      <Author>Matias, P.M., et al.</Author>
      <Journal>J.Biol.Chem.(2000)275:26164</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/10840043?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the androgen receptor ligand binding domain in complex with SARM S-22</PDB_Title>
      <PDB_ID>3RLJ</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3RLJ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Unexpected binding orientation of bulky-B-ring anti-androgens and implications for future drug targets.</PubMed_Title>
      <Author>Duke, C.B., et al.</Author>
      <Journal>J.Med.Chem.(2011)54:3973-3976</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/21506597?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the androgen receptor ligand binding domain in complex with SARM C-23</PDB_Title>
      <PDB_ID>3B67</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3B67</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Effect of B-ring substitution pattern on binding mode of propionamide selective androgen receptor modulators</PubMed_Title>
      <Author>Bohl, C.E., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2008)18:5567-5570</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/18805694?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>The Wild Type Androgen Receptor Ligand Binding Domain Bound with Testosterone and a TIF2 box 3 Coactivator Peptide 740-753</PDB_Title>
      <PDB_ID>2Q7J</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2Q7J</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Modulation of androgen receptor activation function 2 by testosterone and dihydrotestosterone.</PubMed_Title>
      <Author>Askew, E.B., et al.</Author>
      <Journal>J.Biol.Chem.(2007)282:25801-25816</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17591767?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the human androgen receptor T877A mutant ligand-binding domain with cyproterone acetate</PDB_Title>
      <PDB_ID>2OZ7</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2OZ7</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structure of the T877A human androgen receptor ligand-binding domain complexed to cyproterone acetate provides insight for ligand-induced conformational changes and structure-based drug design.</PubMed_Title>
      <Author>Bohl, C.E., et al.</Author>
      <Journal>J.Biol.Chem.(2007)282:13648-13655</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17311914?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Androgen receptor LBD with small molecule</PDB_Title>
      <PDB_ID>2PIO</PDB_ID>
      <Resolution>2.03</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2PIO</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD06710004</ASD_Ligand>
      <PubMed_Title>A surface on the androgen receptor that allosterically regulates coactivator binding.</PubMed_Title>
      <Author>Estebanez-Perpina, E., et al.</Author>
      <Journal>Proc.Natl.Acad.Sci.Usa(2007)104:16074-16079</Journal>
      <PubMed_ID>17911242</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>STRUCTURAL BASIS FOR THE GLUCOCORTICOID RESPONSE IN A MUTANT HUMAN ANDROGEN RECEPTOR (ARCCR) DERIVED FROM AN ANDROGEN-INDEPENDENT PROSTATE CANCER</PDB_Title>
      <PDB_ID>1GS4</PDB_ID>
      <Resolution>1.95</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1GS4</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural Basis for the Glucocorticoid Response in a Mutant Human Androgen Receptor (Ar(Ccr)) Derived from an Androgen-Independent Prostate Cancer</PubMed_Title>
      <Author>Matias, P.M., et al.</Author>
      <Journal>J.Med.Chem.(2002)45:1439</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/11906285?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Complex Androgen Receptor LBD and RAC3 peptide</PDB_Title>
      <PDB_ID>1XJ7</PDB_ID>
      <Resolution>2.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1XJ7</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The Molecular Mechanisms of Coactivator Utilization in Ligand-dependent Transactivation by the Androgen Receptor</PubMed_Title>
      <Author>Estebanez-Perpina, E., et al.</Author>
      <Journal>J.Biol.Chem.(2005)280:8060-8068</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15563469?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>The Androgen Receptor Prostate Cancer Mutant H874Y Ligand Binding Domain Bound with Testosterone and a TIF2 box3 Coactivator Peptide 740-753</PDB_Title>
      <PDB_ID>2Q7L</PDB_ID>
      <Resolution>1.92</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2Q7L</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Modulation of androgen receptor activation function 2 by testosterone and dihydrotestosterone.</PubMed_Title>
      <Author>Askew, E.B., et al.</Author>
      <Journal>J.Biol.Chem.(2007)282:25801-25816</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17591767?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>The Crystal Structure of Ligand-binding Domain (LBD) of human Androgen Receptor in Complex with a selective modulator LGD2226</PDB_Title>
      <PDB_ID>2HVC</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2HVC</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure of the ligand-binding domain (LBD) of human androgen receptor in complex with a selective modulator LGD2226</PubMed_Title>
      <Author>Wang, F., et al.</Author>
      <Journal>ACTA CRYSTALLOGR.,SECT.F(2006)62:1067-1071</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17077481?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>TARGETING THE BINDING FUNCTION 3 SITE OF THE ANDROGEN RECEPTOR THROUGH IN SILICO MOLECULAR MODELING</PDB_Title>
      <PDB_ID>2YLO</PDB_ID>
      <Resolution>2.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2YLO</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD06710054</ASD_Ligand>
      <PubMed_Title>Targeting the Binding Function 3 (Bf3) Site of the Human Androgen Receptor Through Virtual Screening.</PubMed_Title>
      <Author>Lack, N.A., et al.</Author>
      <Journal>J.Med.Chem.(2011)54:8563</Journal>
      <PubMed_ID>22047606</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>The Androgen Receptor Prostate Cancer Mutant H874Y Ligand Binding Domain Bound with Testosterone and an AR 20-30 Peptide</PDB_Title>
      <PDB_ID>2Q7K</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2Q7K</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Modulation of androgen receptor activation function 2 by testosterone and dihydrotestosterone.</PubMed_Title>
      <Author>Askew, E.B., et al.</Author>
      <Journal>J.Biol.Chem.(2007)282:25801-25816</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17591767?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the androgen receptor ligand binding domain in complex with SARM S-4</PDB_Title>
      <PDB_ID>3B68</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3B68</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Effect of B-ring substitution pattern on binding mode of propionamide selective androgen receptor modulators</PubMed_Title>
      <Author>Bohl, C.E., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2008)18:5567-5570</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/18805694?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the human androgen receptor ligand binding domain bound with TIF2(iii) 740-753 peptide and R1881</PDB_Title>
      <PDB_ID>2AO6</PDB_ID>
      <Resolution>1.89</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2AO6</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural basis for androgen receptor interdomain and coactivator interactions suggests a transition in nuclear receptor activation function dominance</PubMed_Title>
      <Author>He, B., et al.</Author>
      <Journal>Mol.Cell(2004)16:425-438</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15525515?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>The Wild Type Androgen Receptor Ligand Binding Domain Bound with Testosterone and an AR 20-30 Peptide</PDB_Title>
      <PDB_ID>2Q7I</PDB_ID>
      <Resolution>1.87</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2Q7I</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Modulation of androgen receptor activation function 2 by testosterone and dihydrotestosterone.</PubMed_Title>
      <Author>Askew, E.B., et al.</Author>
      <Journal>J.Biol.Chem.(2007)282:25801-25816</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17591767?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>TARGETING THE BINDING FUNCTION 3 SITE OF THE ANDROGEN RECEPTOR THROUGH IN SILICO MOLECULAR MODELING</PDB_Title>
      <PDB_ID>2YLQ</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2YLQ</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD06710071</ASD_Ligand>
      <PubMed_Title>Targeting the Binding Function 3 (Bf3) Site of the Human Androgen Receptor Through Virtual Screening.</PubMed_Title>
      <Author>Lack, N.A., et al.</Author>
      <Journal>J.Med.Chem.(2011)54:8563</Journal>
      <PubMed_ID>22047606</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of DHT-bound androgen receptor in complex with the third motif of steroid receptor coactivator 3</PDB_Title>
      <PDB_ID>3L3Z</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3L3Z</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Identification of SRC3/AIB1 as a Preferred Coactivator for Hormone-activated Androgen Receptor.</PubMed_Title>
      <Author>Zhou, X.E., et al.</Author>
      <Journal>J.Biol.Chem.(2010)285:9161-9171</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/20086010?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of the Androgen Receptor Ligand Binding Domain (LBD) with DHT and a peptide derived from its physiological coactivator ARA70</PDB_Title>
      <PDB_ID>1T5Z</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1T5Z</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The Molecular Mechanisms of Coactivator Utilization in Ligand-dependent Transactivation by the Androgen Receptor.</PubMed_Title>
      <Author>Estebanez-Perpina, E., et al.</Author>
      <Journal>J.Biol.Chem.(2005)280:8060-8068</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15563469?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>androgen receptor LBD with small molecule</PDB_Title>
      <PDB_ID>2PIQ</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2PIQ</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD06710008</ASD_Ligand>
      <PubMed_Title>A surface on the androgen receptor that allosterically regulates coactivator binding.</PubMed_Title>
      <Author>Estebanez-Perpina, E., et al.</Author>
      <Journal>Proc.Natl.Acad.Sci.Usa(2007)104:16074-16079</Journal>
      <PubMed_ID>17911242</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the androgen receptor ligand binding domain in complex with SARM S-21</PDB_Title>
      <PDB_ID>3B66</PDB_ID>
      <Resolution>1.65</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3B66</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Effect of B-ring substitution pattern on binding mode of propionamide selective androgen receptor modulators</PubMed_Title>
      <Author>Bohl, C.E., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2008)18:5567-5570</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/18805694?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure Of The Androgen Receptor Ligand Binding Domain In Complex With S-1</PDB_Title>
      <PDB_ID>2AXA</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2AXA</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural Basis for Accommodation of Nonsteroidal Ligands in the Androgen Receptor</PubMed_Title>
      <Author>Bohl, C.E., et al.</Author>
      <Journal>J.Biol.Chem.(2005)280:37747-37754</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16129672?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the T877A androgen receptor ligand binding domain in complex with (S)-N-(4-Cyano-3-(trifluoromethyl)phenyl)-3-(4-cyanonaphthalen-1-yloxy)-2-hydroxy-2-methylpropanamide</PDB_Title>
      <PDB_ID>3RLL</PDB_ID>
      <Resolution>1.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3RLL</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Unexpected binding orientation of bulky-B-ring anti-androgens and implications for future drug targets.</PubMed_Title>
      <Author>Duke, C.B., et al.</Author>
      <Journal>J.Med.Chem.(2011)54:3973-3976</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/21506597?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of the Androgen Receptor Ligand-binding Domain W741L Mutant Complex with R-bicalutamide</PDB_Title>
      <PDB_ID>1Z95</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1Z95</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural basis for antagonism and resistance of bicalutamide in prostate cancer.</PubMed_Title>
      <Author>Bohl, C.E., et al.</Author>
      <Journal>Proc.Natl.Acad.Sci.Usa(2005)102:6201-6206</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15833816?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Androgen receptor LBD with small molecule</PDB_Title>
      <PDB_ID>2PIR</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2PIR</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD06718001</ASD_Ligand>
      <PubMed_Title>A surface on the androgen receptor that allosterically regulates coactivator binding.</PubMed_Title>
      <Author>Estebanez-Perpina, E., et al.</Author>
      <Journal>Proc.Natl.Acad.Sci.Usa(2007)104:16074-16079</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17911242?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the androgen receptor ligand binding domain in complex with minoxidil</PDB_Title>
      <PDB_ID>4K7A</PDB_ID>
      <Resolution>2.44</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4K7A</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD06710074</ASD_Ligand>
      <PubMed_Title>Crystal structure of the androgen receptor ligand binding domain in complex with minoxidil</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure Of The Androgen Receptor Ligand Binding Domain T877A Mutant In Complex With S-1</PDB_Title>
      <PDB_ID>2AX7</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2AX7</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural Basis for Accommodation of Nonsteroidal Ligands in the Androgen Receptor</PubMed_Title>
      <Author>Bohl, C.E., et al.</Author>
      <Journal>J.Biol.Chem.(2005)280:37747-37754</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16129672?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of human androgen receptor ligand-binding domain in complex with EM-5744</PDB_Title>
      <PDB_ID>2PNU</PDB_ID>
      <Resolution>1.65</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2PNU</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural Characterization of the Human Androgen Receptor Ligand-binding Domain Complexed with EM5744, a Rationally Designed Steroidal Ligand Bearing a Bulky Chain Directed toward Helix 12.</PubMed_Title>
      <Author>Cantin, L., et al.</Author>
      <Journal>J.Biol.Chem.(2007)282:30910-30919</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17711855?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure Of The Androgen Receptor Ligand Binding Domain In Complex With R-3</PDB_Title>
      <PDB_ID>2AX9</PDB_ID>
      <Resolution>1.65</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2AX9</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural Basis for Accommodation of Nonsteroidal Ligands in the Androgen Receptor</PubMed_Title>
      <Author>Bohl, C.E., et al.</Author>
      <Journal>J.Biol.Chem.(2005)280:37747-37754</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16129672?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Androgen receptor LBD with small molecule</PDB_Title>
      <PDB_ID>2PKL</PDB_ID>
      <Resolution>2.49</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2PKL</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD06710006</ASD_Ligand>
      <PubMed_Title>A surface on the androgen receptor that allosterically regulates coactivator binding.</PubMed_Title>
      <Author>Estebanez-Perpina, E., et al.</Author>
      <Journal>Proc.Natl.Acad.Sci.Usa(2007)104:16074-16079</Journal>
      <PubMed_ID>17911242</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>AR LBD with small molecule</PDB_Title>
      <PDB_ID>2QPY</PDB_ID>
      <Resolution>2.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2QPY</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD06710006</ASD_Ligand>
      <PubMed_Title>A surface on the androgen receptor that allosterically regulates coactivator binding.</PubMed_Title>
      <Author>Estebanez-Perpina, E., et al.</Author>
      <Journal>Proc.Natl.Acad.Sci.Usa(2007)104:16074-16079</Journal>
      <PubMed_ID>17911242</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of human androgen receptor ligand binding domain in complex with tetrahydrogestrinone</PDB_Title>
      <PDB_ID>2AMB</PDB_ID>
      <Resolution>1.75</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2AMB</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Comparison of crystal structures of human androgen receptor ligand-binding domain complexed with various agonists reveals molecular determinants responsible for binding affinity.</PubMed_Title>
      <Author>Pereira de Jesus-Tran, K., et al.</Author>
      <Journal>Protein Sci.(2006)15:987-999</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16641486?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the androgen receptor ligand binding domain in complex with SARM C-31</PDB_Title>
      <PDB_ID>3B5R</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3B5R</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Effect of B-ring substitution pattern on binding mode of propionamide selective androgen receptor modulators</PubMed_Title>
      <Author>Bohl, C.E., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2008)18:5567-5570</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/18805694?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the human androgen receptor ligand binding domain bound with R1881</PDB_Title>
      <PDB_ID>1XQ3</PDB_ID>
      <Resolution>2.25</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1XQ3</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural basis for androgen receptor interdomain and coactivator interactions suggests a transition in nuclear receptor activation function dominance</PubMed_Title>
      <Author>He, B., et al.</Author>
      <Journal>Mol.Cell(2004)16:425-438</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15525515?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure Of The Androgen Receptor Ligand Binding Domain T877A Mutant In Complex With Hydroxyflutamide</PDB_Title>
      <PDB_ID>2AX6</PDB_ID>
      <Resolution>1.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2AX6</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural Basis for Accommodation of Nonsteroidal Ligands in the Androgen Receptor</PubMed_Title>
      <Author>Bohl, C.E., et al.</Author>
      <Journal>J.Biol.Chem.(2005)280:37747-37754</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16129672?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Androgen receptor LBD with small molecule</PDB_Title>
      <PDB_ID>2PIT</PDB_ID>
      <Resolution>1.76</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2PIT</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD06710006</ASD_Ligand>
      <PubMed_Title>A surface on the androgen receptor that allosterically regulates coactivator binding.</PubMed_Title>
      <Author>Estebanez-Perpina, E., et al.</Author>
      <Journal>Proc.Natl.Acad.Sci.Usa(2007)104:16074-16079</Journal>
      <PubMed_ID>17911242</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of human androgen receptor ligand binding domain in complex with dihydrotestosterone</PDB_Title>
      <PDB_ID>2AMA</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2AMA</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Comparison of crystal structures of human androgen receptor ligand-binding domain complexed with various agonists reveals molecular determinants responsible for binding affinity.</PubMed_Title>
      <Author>Pereira de Jesus-Tran, K., et al.</Author>
      <Journal>Protein Sci.(2006)15:987-999</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16641486?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Androgen receptor LBD with small molecule</PDB_Title>
      <PDB_ID>2PIP</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2PIP</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD06710007;ASD06710009</ASD_Ligand>
      <PubMed_Title>A surface on the androgen receptor that allosterically regulates coactivator binding.</PubMed_Title>
      <Author>Estebanez-Perpina, E., et al.</Author>
      <Journal>Proc.Natl.Acad.Sci.Usa(2007)104:16074-16079</Journal>
      <PubMed_ID>17911242</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of human androgen receptor ligand binding domain in complex with testosterone</PDB_Title>
      <PDB_ID>2AM9</PDB_ID>
      <Resolution>1.64</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2AM9</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Comparison of crystal structures of human androgen receptor ligand-binding domain complexed with various agonists reveals molecular determinants responsible for binding affinity.</PubMed_Title>
      <Author>Pereira de Jesus-Tran, K., et al.</Author>
      <Journal>Protein Sci.(2006)15:987-999</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16641486?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of the Androgen Receptor Ligand Binding Domain with DHT and a peptide derived from its physiological coactivator GRIP1 NR box3</PDB_Title>
      <PDB_ID>1T63</PDB_ID>
      <Resolution>2.07</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1T63</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The Molecular Mechanisms of Coactivator Utilization in Ligand-dependent Transactivation by the Androgen Receptor.</PubMed_Title>
      <Author>Estebanez-Perpina, E., et al.</Author>
      <Journal>J.Biol.Chem.(2005)280:8060-8068</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15563469?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>AR LBD with small molecule</PDB_Title>
      <PDB_ID>2PIX</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2PIX</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD06710002</ASD_Ligand>
      <PubMed_Title>A surface on the androgen receptor that allosterically regulates coactivator binding.</PubMed_Title>
      <Author>Estebanez-Perpina, E., et al.</Author>
      <Journal>Proc.Natl.Acad.Sci.Usa(2007)104:16074-16079</Journal>
      <PubMed_ID>17911242</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>TARGETING THE BINDING FUNCTION 3 SITE OF THE ANDROGEN RECEPTOR THROUGH IN SILICO MOLECULAR MODELING</PDB_Title>
      <PDB_ID>3ZQT</PDB_ID>
      <Resolution>2.29</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3ZQT</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD06710072</ASD_Ligand>
      <PubMed_Title>Targeting the Binding Function 3 (Bf3) Site of the Human Androgen Receptor Through Virtual Screening.</PubMed_Title>
      <Author>Lack, N.A., et al.</Author>
      <Journal>J.Med.Chem.(2011)54:8563</Journal>
      <PubMed_ID>22047606</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the androgen receptor ligand binding domain in complex with SARM S-24</PDB_Title>
      <PDB_ID>3B65</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3B65</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Effect of B-ring substitution pattern on binding mode of propionamide selective androgen receptor modulators</PubMed_Title>
      <Author>Bohl, C.E., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2008)18:5567-5570</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/18805694?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HUMAN ANDROGEN RECEPTOR IN COMPLEX WITH AF2 SMALL MOLECULE INHIBITOR</PDB_Title>
      <PDB_ID>2YHD</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2YHD</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD06710053</ASD_Ligand>
      <PubMed_Title>Inhibitors of Androgen Receptor Activation Function-2 (Af2) Site Identified Through Virtual Screening.</PubMed_Title>
      <Author>Axerio-Cilies, P., et al.</Author>
      <Journal>J.Med.Chem.(2011)54:6197</Journal>
      <PubMed_ID>21846139</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Androgen receptor with small molecule</PDB_Title>
      <PDB_ID>2PIV</PDB_ID>
      <Resolution>1.95</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2PIV</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD06718002</ASD_Ligand>
      <PubMed_Title>A surface on the androgen receptor that allosterically regulates coactivator binding.</PubMed_Title>
      <Author>Estebanez-Perpina, E., et al.</Author>
      <Journal>Proc.Natl.Acad.Sci.Usa(2007)104:16074-16079</Journal>
      <PubMed_ID>17911242</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the human androgen receptor ligand binding domain bound with an androgen receptor NH2-terminal peptide, AR20-30, and R1881</PDB_Title>
      <PDB_ID>1XOW</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1XOW</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural basis for androgen receptor interdomain and coactivator interactions suggests a transition in nuclear receptor activation function dominance</PubMed_Title>
      <Author>He, B., et al.</Author>
      <Journal>Mol.Cell(2004)16:425-438</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15525515?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Androgen receptor LBD with small molecule</PDB_Title>
      <PDB_ID>2PIU</PDB_ID>
      <Resolution>2.12</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2PIU</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD06710006</ASD_Ligand>
      <PubMed_Title>A surface on the androgen receptor that allosterically regulates coactivator binding.</PubMed_Title>
      <Author>Estebanez-Perpina, E., et al.</Author>
      <Journal>Proc.Natl.Acad.Sci.Usa(2007)104:16074-16079</Journal>
      <PubMed_ID>17911242</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure Of The Androgen Receptor Ligand Binding Domain W741L Mutant In Complex With S-1</PDB_Title>
      <PDB_ID>2AX8</PDB_ID>
      <Resolution>1.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2AX8</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural Basis for Accommodation of Nonsteroidal Ligands in the Androgen Receptor</PubMed_Title>
      <Author>Bohl, C.E., et al.</Author>
      <Journal>J.Biol.Chem.(2005)280:37747-37754</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16129672?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Targeting the Binding Function 3 (BF3) Site of the Human Androgen Receptor Through Virtual Screening. 2. Development of 2-((2-phenoxyethyl) thio)-1H-benzoimidazole derivatives.</PDB_Title>
      <PDB_ID>4HLW</PDB_ID>
      <Resolution>2.5</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4HLW</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD06710073</ASD_Ligand>
      <PubMed_Title>Targeting the Binding Function 3 (BF3) Site of the Androgen Receptor Through Virtual Screening. 2. Development of 2-((2-phenoxyethyl) thio)-1H-benzimidazole Derivatives.</PubMed_Title>
      <Author>Munuganti, R.S., et al.</Author>
      <Journal>J.Med.Chem.(2013)56:1136-1148</Journal>
      <PubMed_ID>23301637</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>AR-NLS:Importin-alpha complex</PDB_Title>
      <PDB_ID>3BTR</PDB_ID>
      <Resolution>2.6</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3BTR</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural basis for the nuclear import of the human androgen receptor</PubMed_Title>
      <Author>Cutress, M.L., et al.</Author>
      <Journal>J.Cell.Sci.(2008)121:957-968</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/18319300?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of AR LBD with SHP peptide NR Box 2</PDB_Title>
      <PDB_ID>2Z4J</PDB_ID>
      <Resolution>2.6</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2Z4J</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Interaction between the androgen receptor and a segment of its corepressor SHP</PubMed_Title>
      <Author>Jouravel, N., et al.</Author>
      <Journal>Acta Crystallogr.,Sect.D(2007)63:1198-1200</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/18007036?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of DHT-bound androgen receptor in complex with the first motif of steroid receptor coactivator 3</PDB_Title>
      <PDB_ID>3L3X</PDB_ID>
      <Resolution>1.55</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3L3X</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Identification of SRC3/AIB1 as a Preferred Coactivator for Hormone-activated Androgen Receptor.</PubMed_Title>
      <Author>Zhou, X.E., et al.</Author>
      <Journal>J.Biol.Chem.(2010)285:9161-9171</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/20086010?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the androgen receptor ligand binding domain with DHT and a peptide derived form its physiological coactivator GRIP1 NR box 2 bound in a non-helical conformation</PDB_Title>
      <PDB_ID>1T65</PDB_ID>
      <Resolution>1.66</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1T65</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The Molecular Mechanisms of Coactivator Utilization in Ligand-dependent Transactivation by the Androgen Receptor.</PubMed_Title>
      <Author>Estebanez-Perpina, E., et al.</Author>
      <Journal>J.Biol.Chem.(2005)280:8060-8068</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15563469?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Androgen receptor with small molecule</PDB_Title>
      <PDB_ID>2PIW</PDB_ID>
      <Resolution>2.58</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2PIW</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD06718002</ASD_Ligand>
      <PubMed_Title>A surface on the androgen receptor that allosterically regulates coactivator binding.</PubMed_Title>
      <Author>Estebanez-Perpina, E., et al.</Author>
      <Journal>Proc.Natl.Acad.Sci.Usa(2007)104:16074-16079</Journal>
      <PubMed_ID>17911242</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>TARGETING THE BINDING FUNCTION 3 SITE OF THE ANDROGEN RECEPTOR THROUGH IN SILICO MOLECULAR MODELING</PDB_Title>
      <PDB_ID>2YLP</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2YLP</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD06710069</ASD_Ligand>
      <PubMed_Title>Targeting the Binding Function 3 (Bf3) Site of the Human Androgen Receptor Through Virtual Screening.</PubMed_Title>
      <Author>Lack, N.A., et al.</Author>
      <Journal>J.Med.Chem.(2011)54:8563</Journal>
      <PubMed_ID>22047606</PubMed_ID>
    </PDB>
  </PDB_List>
  <Network_List>
    <Network>
      <Pathway_ID>ko05215</Pathway_ID>
      <Pathway_Title>Prostate cancer</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cancers</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05200</Pathway_ID>
      <Pathway_Title>Pathways in cancer</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cancers</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05200</Pathway_ID>
      <Pathway_Title>Pathways in cancer</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cancers</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05215</Pathway_ID>
      <Pathway_Title>Prostate cancer</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cancers</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04114</Pathway_ID>
      <Pathway_Title>Oocyte meiosis</Pathway_Title>
      <Pathway_Class>Cellular Processes</Pathway_Class>
      <Pathway_Subclass>Cell growth and death</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05215</Pathway_ID>
      <Pathway_Title>Prostate cancer</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cancers</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05200</Pathway_ID>
      <Pathway_Title>Pathways in cancer</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cancers</Pathway_Subclass>
    </Network>
  </Network_List>
  <Fold>
    <SCOP_Class>All alpha proteins</SCOP_Class>
    <SCOP_URL>http://scop.mrc-lmb.cam.ac.uk/scop/data/scop.b.b.cdh.b.b.be.html</SCOP_URL>
    <CATH_Class>Class 1: Mainly Alpha</CATH_Class>
    <CATH_URL>http://www.cathdb.info/pdb/1e3g</CATH_URL>
  </Fold>
  <AllostericSite_List>
    <AllostericSite>
      <Site_Detail>site,673,Phe;site,829,Glu;site,833,Asn;site,834,Tyr;site,840,Arg</Site_Detail>
      <Site_Reference>Estbanez-Perpi E, et al. Proc Natl Acad Sci U S A. 2007;104(41):16074-16079</Site_Reference>
      <PDB_ID>2PIT;2PIU;2PIX;2PKL</PDB_ID>
      <PubMed_ID>17911242</PubMed_ID>
    </AllostericSite>
  </AllostericSite_List>
  <Modulator_List>
    <Modulator>
      <ASD_ID>ASD01140141</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD06710001</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD06710002</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD06710003</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD06710004</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD06710005</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD06710006</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD06710007</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD06710008</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD06710009</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD06710010</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD06710011</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD06710012</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD06710013</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD06710014</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD06710015</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD06710017</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD06710018</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD06710019</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD06710020</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD06710022</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD06710023</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD06710024</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD06710025</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD06710026</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD06710027</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD06710028</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD06710029</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD06710036</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD06710037</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD06710040</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD06710041</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD06710042</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD06710043</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD06710044</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD06710045</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD06710046</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD06710047</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD06710048</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD06710049</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD06710050</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD06710051</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD06710053</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD06710054</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD06710055</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD06710056</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD06710057</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD06710058</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD06710059</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD06710060</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD06710061</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD06710062</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD06710063</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD06710064</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD06710065</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD06710066</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD06710067</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD06710068</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD06710069</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD06710071</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD06710072</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD06710073</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD06710074</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD06718001</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD06718002</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
  </Modulator_List>
  <Create_Date>2012-06-20</Create_Date>
</Organism_Record>